"A great boost to pharma industry in terms of R&D": KPMG

01 February 2023 | Views

Vijay Chawla, Partner and Head, Life Sciences, and Head, Risk Advisory, KPMG in India shares his reaction on Union Budget 2023-24

"The Budget has given a great boost to the pharma industry in terms of R&D. Introduction of this scheme through various centres of excellence (CoE) will also help attract industry players to invest in R&D. Dedicated multidisciplinary courses for medical devices in existing institutions will ensure availability of skilled manpower for futuristic medical technologies, high-end manufacturing and research. Overall this is a much needed force for the pharma sector."

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account